Blog

Sara Tolaney: Beautiful discussion of EMBER-3 by Harold Burstein

Collage photo of Sara Tolaney and Harold Burstein

Dec 12, 2024, 20:45

Sara Tolaney: Beautiful discussion of EMBER-3 by Harold Burstein

Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, shared a post on X:

“Beautiful discussion of EMBER-3 by Harold Burstein.

Benefit for Imlunestrant and abemaciclib seen irrespective of ESR1m or PI3Km, and seen in the post cdk 4/6i subgroup

Put into clinical context perfectly!”

More posts featuring Sara Tolaney.

Read the post “Highlights from Day 1 of SABCS 2024 by Sara Tolaney” on oncodaily.com.

Sara Tolaney is the Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute. She also serves as Associate Director of the Susan F. Smith Center for Women’s Cancers and is a Senior Physician at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School.

Her research focuses on the development of novel therapies in the treatment of breast cancer and developing more effective and less toxic treatment approaches. Her work has demonstrated that a relatively low risk regimen is beneficial in women with early stage node-negative HER2-positive cancers, and this works has been incorporated into national and international guidelines.

She has developed several follow-up studies looking at novel approaches to early stage HER2-positive disease and has also played a significant role in development of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy in breast cancer. She is the author of over 150 peer-reviewed publications in leading scientific journals.

She is the recipient of the Lee M Nadler “Extra Mile” Award, and the Innovation Award for Clinical Faculty.